Annexon Q1 net loss $25.2M; cash $264.9M; Phase 3 GBS data due Q2 2024

Annexon, Inc.

2024-Q1 EPS reported -$0.21

Net loss $25.2M ($0.21/share) vs $38.7M ($0.52) in Q1 2023; R&D spend $21M vs $32.3M.
Cash, equivalents & short-term investments $264.9M as of March 31, 2024, runway into mid-2026.
Topline Phase 3 data for ANX005 in Guillain-Barré Syndrome expected Q2 2024.
Pivotal Phase 3 ARCHER II trial for ANX007 in geographic atrophy to start mid-2024; ARROW head-to-head vs SYFOVRE planned H2 2024.
Proof-of-concept data for oral ANX1502 in cold agglutinin disease on track for H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Annexon, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 13, 2024, Annexon, Inc. (the “Company”) announced certain financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Annexon, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-058629

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.